MX392701B - Composiciones de mieloperoxidasa y métodos para la inhibición de lipopolisacáridos y lípido a. - Google Patents

Composiciones de mieloperoxidasa y métodos para la inhibición de lipopolisacáridos y lípido a.

Info

Publication number
MX392701B
MX392701B MX2018013925A MX2018013925A MX392701B MX 392701 B MX392701 B MX 392701B MX 2018013925 A MX2018013925 A MX 2018013925A MX 2018013925 A MX2018013925 A MX 2018013925A MX 392701 B MX392701 B MX 392701B
Authority
MX
Mexico
Prior art keywords
lipid
methods
lipopolysaccharides
inhibiting
compositions
Prior art date
Application number
MX2018013925A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013925A (es
Inventor
Robert C Allen
Original Assignee
Exoxemis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exoxemis Inc filed Critical Exoxemis Inc
Publication of MX2018013925A publication Critical patent/MX2018013925A/es
Publication of MX392701B publication Critical patent/MX392701B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2018013925A 2016-05-27 2017-04-13 Composiciones de mieloperoxidasa y métodos para la inhibición de lipopolisacáridos y lípido a. MX392701B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342382P 2016-05-27 2016-05-27
PCT/US2017/027458 WO2017204918A1 (en) 2016-05-27 2017-04-13 Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a

Publications (2)

Publication Number Publication Date
MX2018013925A MX2018013925A (es) 2019-03-28
MX392701B true MX392701B (es) 2025-03-24

Family

ID=60411564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013925A MX392701B (es) 2016-05-27 2017-04-13 Composiciones de mieloperoxidasa y métodos para la inhibición de lipopolisacáridos y lípido a.

Country Status (9)

Country Link
US (1) US11389514B2 (enExample)
EP (1) EP3463431B1 (enExample)
JP (3) JP6713546B2 (enExample)
CN (1) CN109414485B (enExample)
AU (1) AU2017269582B2 (enExample)
CA (1) CA3022426C (enExample)
IL (1) IL262930B2 (enExample)
MX (1) MX392701B (enExample)
WO (1) WO2017204918A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3820996A4 (en) * 2018-07-13 2022-04-27 Robert C. Allen HALOPEROXIDASES COMPOSITIONS AND USES THEREOF
WO2022103565A1 (en) * 2020-11-13 2022-05-19 Exoxemis, Inc. Myeloperoxidase-containing compositions and uses thereof
EP4633655A1 (en) * 2022-12-14 2025-10-22 Universite De Bordeaux Artificial bifunctional enzyme comprising a myeloperoxidase activity and a glucose oxidase activity and applications thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2108387B (en) 1979-12-28 1984-03-21 Green Cross Corp A pharmaceutical composition containing myeloperoxidase
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5622848A (en) * 1990-05-23 1997-04-22 Medical Discoveries, Inc. Electrically hydrolyzed salines as microbiocides for in vitro treatment of contaminated fluids containing blood
WO1992014484A1 (en) 1991-02-21 1992-09-03 Exoxemis, Inc. Methods and compositions for the treatment of infection and control of flora
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
US5888505A (en) * 1991-02-21 1999-03-30 Eoe, Inc. Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system
US5565197A (en) * 1991-02-21 1996-10-15 Exoxemis, Inc. Method which utilizes a haloperoxidase composition to inhibit the growth of microorganisms which cause sexually transmitted diseases
US8945540B2 (en) * 2008-05-09 2015-02-03 Exoxemis, Inc. Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof
BR112014000542A2 (pt) * 2011-07-11 2017-02-14 Exoxemis Inc composições de peroxidase eosinofílica e métodos de uso das mesmas

Also Published As

Publication number Publication date
IL262930B1 (en) 2023-07-01
CN109414485B (zh) 2022-08-12
US11389514B2 (en) 2022-07-19
EP3463431C0 (en) 2024-09-18
JP6713546B2 (ja) 2020-06-24
CA3022426C (en) 2023-05-16
JP2019515881A (ja) 2019-06-13
EP3463431B1 (en) 2024-09-18
JP2020111620A (ja) 2020-07-27
WO2017204918A1 (en) 2017-11-30
IL262930B2 (en) 2023-11-01
EP3463431A4 (en) 2020-01-15
CA3022426A1 (en) 2017-11-30
AU2017269582B2 (en) 2023-12-21
MX2018013925A (es) 2019-03-28
JP2021181500A (ja) 2021-11-25
CN109414485A (zh) 2019-03-01
IL262930A (en) 2018-12-31
US20190183983A1 (en) 2019-06-20
AU2017269582A1 (en) 2018-10-04
EP3463431A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1123196T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1123441T1 (el) Μορια με ειδικοτητα στα cd45 και cd79
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
MD3359172T2 (ro) Compoziții care conțin tulpini bacteriene
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
BR112018009184A2 (pt) composições compreendendo cepas bacterianas
BR112018009706A8 (pt) composições compreendendo cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
MX379270B (es) Composiciones que comprenden cepas bacterianas.
MX383852B (es) Composiciones que comprenden cepas bacterianas.
MX375352B (es) Reguladores de nrf2.
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
BR112016006048A8 (pt) composições antimicrobianas
UY33938A (es) Artículo para fumar que incluye dos o más segmentos de filtro
MX386008B (es) Compuestos citotóxicos y antimitóticos, y métodos para utilizarlos.
MX392701B (es) Composiciones de mieloperoxidasa y métodos para la inhibición de lipopolisacáridos y lípido a.
BR112017023969A2 (pt) ?microrganismo do gênero escherichia que produz l-triptofano e um método para produzir l- triptofano com o uso do mesmo?
CL2018001680A1 (es) Composiciones y métodos de uso de nuevas cepas de lactobacillus fermentum
BR112016028948A2 (pt) ?composição bifásica?
MX2016009094A (es) Composiciones de heme-haloperoxidasa bioactiva y sus metodos de uso.
CL2016003351A1 (es) Lipido que comprende ácido docosapentanoico
MX394471B (es) Composiciones y métodos para desgomar aceite.
AU2017257061A1 (en) Lipophosphonoxins of second generation, and their use